Title slide

Startups

2 | Copyright © 2020 All Rights Reserved.

 Proxygen Evaluation Status Wait and see
Attendee
Meeting date 3/1/2021 Attendee Bernhard Boidol Yoshiharu Mizui
from EII
Name Proxygen Location Vienna, Austria Establish 2020
Contact info Bernhard Boidol Email address [email protected]
O/N/Digital O/N Attached doc □ No 　　■ Yes ( )
Stage Unknown Investors Unknown Valuation Unknown
URL https://proxygen.com/
Specialize in a completely different class of drugs, called molecular glue degraders.
Instead of merely inhibiting a harmful protein’s function, molecular glue degraders
Overview
eliminate the protein completely. They do this by reprogramming the natural protein
recycling machinery present in every cell.
Synergy Molecular glue is one of targets of interests for both OBG and NBG
Fund raising Unknown at this point
Technology itself looks interesting, but this platform’s value is not confirmed yet. It’s
Comment good to continue communication for the timing of investment and partnering. HRL (Peter
and James) introduced this meeting opportunity. James is contact person to Proxygen.
3 | Copyright © 2020 All Rights Reserved.
 iBody Inc. Evaluation Status Decline

Attendee
Meeting date 3/2/2021 Attendee Shoji Ohuchi Yoshiharu Mizui
from EII
(CSO,PhD)
Name iBody Inc. Location Nagoya, Japan Establish 2018
Contact info Shoji Ohuchi Email address amakusa.yo@ibody,co.jp
O/N/Digital Oncology Attached doc □ No 　　■ Yes ( Non-con Deck )
Stage Unknown Investors Nssay BioCapital Valuation Unknown
URL https://www.ibody.co.jp/home-english
They will contribute to the improvement of human health and QOL by developing new
Overview antibody therapeutics using our unique technology "Ecobody " that can discover natural
human antibodies from the human body.
Patients derived mAbs are very common way. It’s not clear what is new in iBody with the
Synergy
limited information.
Fund raising 150 million yen for the development of their pipeline
Comment the 2nd Kyoto University LifeScience Showcase @San Diego 2021

4 | Copyright © 2020 All Rights Reserved.

 Epsilon Molecular Engineering Evaluation Status Decline
Masayuki Tsuchiya, Attendee
Meeting date 3/2/2021 Attendee Yoshiharu Mizui
Shigehiro Sawara from EII
Epsilon Molecular
Name Location Saitama, Japan Establish 2016
Engineering
Masayuki Email
Contact info [email protected]
Tsuchiya address
Attached
O/N/Digital Oncology □ No 　　■ Yes ( Non-con Deck )
doc
Mitsubishi UFJ
Stage Series A Investors Valuation Unknown
Capital
URL http://www.epsilon-mol.co.jp/
EME is developing new modality and replacing the market for antibody drugs with their
Overview products using our high quality, large diversity, and high throughput screening
technology.
Synergy Differentiation point is not clear. Further details needed to understand competitive edge
Fund raising JPY 570 million completed Dec 23, 2020
Comment the 2nd Kyoto University LifeScience Showcase @San Diego 2021
5 | Copyright © 2020 All Rights Reserved.
 aceRNA Technologies Evaluation Status Decline
Teruo Susumu Attendee
Meeting date 3/2/2021 Attendee Yoshiharu Mizui
Fumihiro Sugawa from EII
aceRNA
Name Location Kyoto, Japan Establish 2018
Technologies
Fumihiro Sugawa [email protected]
Contact info Email address
Teruo Susumu [email protected]
O/N/Digital Oncology Attached doc □ No 　　■ Yes ( Non-con Deck )
Stage Series B Investors Unknown Valuation Unknown
URL https://acernatec.com/
aceRNA Technologies has developed two “RNA switch” technologies that form their
platform. First technology is RNA switch, which enables to regulate transgene of interest
by miRNA. We have developed two types of switches. OFF switch; if target miRNA is
Overview active in cells, transgene expression is repressed. ON switch; if target miRNA is active in
cells, transgene expression is promoted. Second technology is RNA switch library, which
is GFP reporter type RNA switch for >2,600 all human miRNAs and enables to identify
cell-specific miRNA activity.
Synergy This might be useful as part of gene therapy, but there is no urgent need at this moment
Fund raising targeting to raise a ¥400 million Series B in mid-2021.
6 | Copyright © 2020 All Rights Reserved.